RxDoctor Payments Data

Kombiz Klein, DO

Internal Medicine · Durham, NCNPI 1619976297

Payments from drug & device makers

$8,081in general payments, 2019–2025

Across 483 payments — averaging $16.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Pfizer$802
  • AbbVie$750
  • Lilly USA, LLC$724
  • Boehringer Ingelheim$684
  • AstraZeneca$326
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$8,045100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,081 in reported general payments places this provider in the 90th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$117,475
Medicare patients
316
Services billed
1,402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide163$182,653
EliquisApixaban167$134,709
TrulicityDulaglutide89$97,956
FarxigaDapagliflozin Propanediol68$74,099
JardianceEmpagliflozin43$60,716
MounjaroTirzepatide54$51,802
RybelsusSemaglutide45$49,164
Repatha SureclickEvolocumab32$38,965
XareltoRivaroxaban29$29,744
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$29,300
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog39$26,132
Breo ElliptaFluticasone/Vilanterol52$23,032
Synjardy XrEmpagliflozin/Metformin Hcl12$18,761
JanuviaSitagliptin Phosphate13$16,725
Repatha SyringeEvolocumab23$12,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,099$231,817208 claims
Lilly USA, LLCTrulicity, Mounjaro$724$149,759143 claims
PfizerEliquis$802$134,709167 claims
Boehringer IngelheimJardiance, Synjardy Xr$684$79,47755 claims
AstraZenecaFarxiga$326$74,09968 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta$210$73,582159 claims
Johnson & JohnsonXarelto$277$29,74429 claims
MerckJanuvia$257$16,72513 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$219$7,59520 claims
AbbVieSynthroid$750$6,65287 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$11$3,037291 claims
IBSA Pharma Inc.Tirosint$71$2,88612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Durham

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →